Private company

Impel Neuropharma (United States)

American pharmaceutical preparations company based in Seattle, founded in 20081

In its 2023 annual report the company says: “We are a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the Central Nervous System, or CNS.”41

Last updated Oct 20, 2026.

Overview

Jan 1, 2008Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSeattle1
  • Websitewww.impelneuropharma.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address201 Elliott Ave. W, Suite 260, Seattle, Wa 981194
  • Filer category, Emerging growth company4
  • LEI549300OM070Y5YFLMR843
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O NATIONAL REGISTERED AGENTS, INC., 19904 Dover, United States3
  • Registered withDivision of Corporations, Department of State, 45793373

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

48.7%Gross margin5
-657.5%Operating margin5
-840.3%Net margin5
1794.0%Revenue growth, 20225
-$95.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue36¢$6.5M
  • Research and development64¢$11.5M

Out of $12.7M in revenue.5 The company lost money this year.

Financial statements

Revenue5$12.7M in 2022+1794% since 2021
0$5.0M$10.0M$15.0M2021: $668.0K$668.0K20212022: $12.7M$12.7M2022+1794%
Gross profit5$6.2M in 2022+26670% since 2021
0$2.0M$4.0M$6.0M$8.0M2021: $23.0K$23.0K20212022: $6.2M$6.2M2022+26670%
Operating income65-$83.2M in 2022+83% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$45.3M-$45.3M20202021: -$71.5M-$71.5M2021+58%2022: -$83.2M-$83.2M2022+16%
Net income65-$106.3M in 2022+132% since 2020
-$150.0M-$100.0M-$50.0M02020: -$45.8M-$45.8M20202021: -$76.5M-$76.5M2021+67%2022: -$106.3M-$106.3M2022+39%
Fiscal year2019202020212022
Revenue$668.0K5$12.7M5
Cost of revenue$691.0K5$6.5M5
Gross profit$23.0K5$6.2M5
Research and development$28.3M6$20.6M5$11.5M5
Operating expenses$71.5M5$89.3M5
Operating income-$45.3M6-$71.5M5-$83.2M5
Income before tax-$76.5M5-$106.3M5
Income tax$1.0K6$2.0K5$05
Net income-$45.8M6-$76.5M5-$106.3M5
Earnings per share-$5.255-$4.535
Earnings per share (diluted)-$5.255-$4.535
Shares (weighted, basic)14.6M shares523.4M shares5
Shares (weighted, diluted)14.6M shares523.4M shares5

Compare Impel Neuropharma (United States) with another company

What it owns

What Impel Neuropharma (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$9.0M5 Dec 31, 2022$7.1M5 Dec 31, 2021+27.1%
Accumulated depreciation$5.1M5 Dec 31, 2022$3.9M5 Dec 31, 2021+30.7%
Property and equipment, net$3.9M5 Dec 31, 2022$3.1M5 Dec 31, 2021+22.7%
Operating-lease assets (leased space)$3.1M5 Dec 31, 2022$05 Dec 31, 2021

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$60.7M5 Dec 31, 2022$88.2M5 Dec 31, 2021−31.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$8.4M5 Dec 31, 2022$2.8M5 Dec 31, 2021+198.4%
Raw materials$2.5M5 Dec 31, 2022$1.0M5 Dec 31, 2021+140.3%
Work in process$4.2M5 Dec 31, 2022$876.0K5 Dec 31, 2021+378.4%
Finished goods$3.3M5 Dec 31, 2022$924.0K5 Dec 31, 2021+260.8%

Leadership

Who has led Impel Neuropharma (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Adrian Adams2021–2023

President

  1. Adrian Adams2021–2023

Chief financial officer

  1. John Harold Leaman2021
  2. Rajiv Amin2023
  3. Michael Wayne Kalb2023
2010201520202025
Board members and other officers (12)

Former names

  • IMPEL PHARMACEUTICALS INCApr 26, 2022 to Feb 15, 20244
  • IMPEL NEUROPHARMA INCSep 15, 2008 to Apr 14, 20224

Timeline

  1. Mar 12, 20248-K Bylaws or fiscal year changed24
  2. Feb 14, 20248-K Entered a material agreement; Bankruptcy or receivership; Completed an acquisition or sale25
  3. Jan 2, 20248-K Other events26
  4. Dec 20, 20238-K Entered a material agreement; Bankruptcy or receivership; Debt or obligation accelerated27
  5. Dec 18, 20238-K Listing notice or transfer28
  6. Dec 4, 20238-K Executive or director change29
  7. Nov 14, 20238-K Executive or director change30
  8. Nov 2, 20238-K Executive or director change31
  9. Oct 16, 20238-K Listing notice or transfer32
  10. Oct 4, 20238-K Entered a material agreement; New debt or obligation; Listing notice or transfer33
  11. Sep 19, 20238-K Regulation FD disclosure34
  12. Sep 7, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares35
  13. Apr 22, 2021New chief executive Adrian Adams becomes CEO9
  14. Jan 1, 2008Founded Founded1

Calendar

When it reported results

  1. May 12, 2023Reported quarterly or annual results36
  2. May 16, 2022Reported quarterly or annual results37
  3. Mar 24, 2022Reported quarterly or annual results38
  4. Nov 15, 2021Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

106 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 33 major events, 40 insider forms, 23 other. The latest 20:

  1. Apr 9, 20244 EDGAR
  2. Apr 9, 20244 EDGAR
  3. Apr 9, 20244 EDGAR
  4. Mar 26, 202415-12G EDGAR
  5. Mar 12, 20248-K EDGAR
  6. Feb 15, 2024EFFECT EDGAR
  7. Feb 14, 2024S-8 POS EDGAR
  8. Feb 14, 2024S-8 POS EDGAR
  9. Feb 14, 2024S-8 POS EDGAR
  10. Feb 14, 2024POS AM EDGAR
  11. Feb 14, 20248-K EDGAR
  12. Jan 2, 20248-K EDGAR
  13. Dec 26, 20233 FORM 3 SUBMISSION EDGAR
  14. Dec 20, 20238-K EDGAR
  15. Dec 19, 20234 EDGAR
  16. Dec 18, 20238-K EDGAR
  17. Dec 4, 20238-K EDGAR
  18. Dec 4, 20234 EDGAR
  19. Dec 4, 20234 EDGAR
  20. Dec 4, 20234 EDGAR

The 106 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 1 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 19, 2023Vivo Capital Surplus Fund VIII, L.P.10% ownerSale237,289$0.08$19.0KForm 4
Dec 18, 2023Vivo Capital Surplus Fund VIII, L.P.10% ownerSale237,711$0.11$26.1KForm 4
Dec 15, 2023Vivo Capital Surplus Fund VIII, L.P.10% ownerSale100,000$0.29$29.0KForm 4
Nov 19, 2021NELSON TIMOTHY SDirectorBuy10,000$10.76$107.6KForm 4

From Forms 4 filed with the SEC.

SEC filer profile

How Impel Neuropharma (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIPI Legacy Liquidation Co2
  • CIK0001445499
  • Employer ID (EIN)26-30582382
  • Filer status<br>emerging growth company2
  • Incorporated inDelaware2
  • Fiscal year endsApril 262
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address201 Elliott Ave. W, Suite 260, Seattle, WA 981192
  • Phone206-568-14662
  • Shares outstanding23,900,031 as of Nov 8, 20238
  • Public float$119.7M as of Jun 30, 202240
  • On EDGAR sinceSep 15, 20082
  • Filings206 in all: 4 (57), 8-K (36), 3 (23), D (16), 10-Q (9), CORRESP (8), UPLOAD (5), EFFECT (4)2
    All 38 form types

    S-8 POS (4), SC 13G (4), S-8 (3), SC 13D/A (3), 10-K (2), 4/A (2), 424B5 (2), DEF 14A (2), DEFA14A (2), DRS (2), S-1 (2), SC 13D (2), 10-K/A (1), 144 (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B1 (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), DRS/A (1), DRSLTR (1), NT 10-Q (1), POS AM (1), PRE 14A (1), REGDEX (1), S-1/A (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Mar 12, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41